Sobrevida alejada de los pacientes con estenosis aórtica severa tratados con implante valvular percutáneo

Autores/as

  • Luis Pérez Hospital Guillermo Grant Benavente
  • Reinaldo Venegas Hospital Guillermo Grant Benavente Facultad de Medicina, Universidad de Concepcion
  • Guillermo Ibieta Hospital Guillermo Grant Benavente
  • Eduardo Lecannelier Hospital Guillermo Grant Benavente, Facultad de Medicina, Universidad de Concepcion
  • Aleck Stockins Hospital Guillermo Grant Benavente
  • Eugenio Sanhueza Hospital Guillermo Grant Benavente
  • Fabrizio Fasce Hospital Guillermo Grant Benavente
  • Alicex González Hospital Guillermo Grant Benavente
  • Jatún Sáez Hospital Guillermo Grant Benavente
  • Constanza Sandoval Hospital Guillermo Grant Benavente
  • Virginia Segall Hospital Guillermo Grant Benavente
  • Isabel Robles Hospital Guillermo Grant Benavente

Palabras clave:

Aortic Valve Stenosis, Heart Valve Disease, Transcatheter Aortic Valve Implantation

Resumen

Background: Transcatheter aortic valve implantation (TAVI) is an effective and safe option for low, medium and high-risk patients with severe aortic stenosis (SAS). Aim: To analyze the clinical results and long-term survival of TAVI in our center. Material and methods: Prospective analysis of 53 patients aged 73 ± 10 years with a Society of Thoracic Surgeons (STS) score of 7.3±3.9%. Results: In 96% a transfemoral access was used and, in most patients, ProGlides™ as vascular closure device was used. General anesthesia and conscious sedation were used in 79 and 21% of cases, respectively. Fifty-three valves were implanted, 42 self-expandable (SEV) and 11 balloon-expandable (Edwards Sapiens). The implant was successful in 52 patients (98%). The transaortic gradient after TAVI was almost zero mmHg in all patients and one had a severe aortic regurgitation. Permanent pacemakers were needed in 17% of patients. Two patients had a pericardial effusion, and one had a major vascular complication. No strokes were recorded, and 30-day mortality was 3.7%. At long-term follow up (23.4 ± 21.6 months) the global survival was 85% and the rate of cardiovascular mortality was 5.9%. Conclusions: In this series of intermediate to high-risk patients, TAVI was associated with an excellent early and long-term survival.

Biografía del autor/a

Luis Pérez, Hospital Guillermo Grant Benavente

Jefe Laboratorio de Hemodinamia

Descargas

Publicado

2021-03-30

Cómo citar

Pérez, L., Venegas, R., Ibieta, G., Lecannelier, E., Stockins, A., Sanhueza, E., Fasce, F., González, A., Sáez, J., Sandoval, C., Segall, V., & Robles, I. (2021). Sobrevida alejada de los pacientes con estenosis aórtica severa tratados con implante valvular percutáneo. Revista Médica De Chile, 149(4). Recuperado a partir de https://revistamedicadechile.cl/index.php/rmedica/article/view/8891

Número

Sección

Artículos de Investigación

Artículos más leídos del mismo autor/a